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Background: Cancer of the uterine cervix is the leading cause of cancer-related death among women in Sub-Saharan
Africa, but information from the Democratic Republic of the Congo (DRC) is scarce. The study objectives were to: 1/
assess prevalence of (pre)cancerous cervical lesions in adult women in Kinshasa, 2/ identify associated socio-
demographic and behavioural factors and 3/ describe human papillomavirus (HPV) types in cervical lesions.
Methods: A cross-sectional study was conducted in Kinshasa. Between 2006 and 2013, four groups of women
were recruited. The first two groups were included at HIV screening centres. Group 1 consisted of HIV-positive and
group 2 of HIV-negative women. Group 3 was included in large hospitals and group 4 in primary health centres.
Pap smears were studied by monolayer technique (Bethesda classification). Low- or high-grade squamous
intraepithelial lesions or carcinoma were classified as LSIL+. HPV types were determined by INNO-LiPA®. Bivariate
and multivariable analyses (logistic regression and generalised estimating equations (GEE)) were used to assess
associations between explanatory variables and LSIL+.
Results: LSIL+ lesions were found in 76 out of 1018 participants. The prevalence was 31.3 % in group 1 (n = 131
HIV-positive women), 3.9 % in group 2 (n = 128 HIV-negative women), 3.9 % in group 3 (n = 539) and 4.1 % in
group 4 (n = 220). The following variables were included in the GEE model but did not reach statistical significance:
history of abortion, ≥3 sexual partners and use of chemical products for vaginal care. In groups 3 and 4 where this
information was available, the use of plants for vaginal care was associated with LSIL+ (adjusted OR 2.70 (95 %
confidence interval 1.04 – 7.01). The most common HPV types among HIV-positive women with ASCUS+ cytology
(ASCUS or worse) were HPV68 (12 out of 50 samples tested), HPV35 (12/50), HPV52 (12/50) and HPV16 (10/50).
Among women with negative/unknown HIV status, the most common types were HPV52 (10/40), HPV35, (6/40)
and HPV18 (5/40).
Conclusion: LSIL+ lesions are frequent among women in Kinshasa. The use of plants for vaginal care deserves
attention as a possible risk factor for LSIL+. In this setting, HPV16 is not the most frequent genotype in samples of
LSIL+ lesions.
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Cervical cancer constitutes a major health problem world-
wide. It is responsible for 530,000 new cases of cancer and
causes 270,000 deaths each year [1, 2]. Up to 80–85 % of
cervical cancer-related deaths occur in low-income coun-
tries [1, 3]. In African women, it is the second most com-
mon cancer after breast cancer with an incidence rate of
about 25 per 100,000 women per year. In Sub-Saharan Af-
rica the incidence rate amounts to about 30–35, and here
it is the most frequent cancer in women (for African data
see [3–6]). It is expected, even on demographic grounds,
that the burden of cervical cancer will further increase in
Africa over the next years [7]. In contrast, in high-income
countries such as the US and Europe the age-standardized
incidence rate is about 6 to 10 per 100,000 women per year
[1, 2]. Also the number of deaths from cervical cancer is
nearly ten times lower in high-income countries [8, 9]. Dif-
ferences between low- and high-income countries have
been related to differences in exposure to risk factors and
adequacy of screening. The most important risk factor is
human papillomavirus (HPV) infection. Several other fac-
tors have been found to increase the risk of cervical cancer,
possibly through their relation with the risk of HPV infec-
tion: number of sexual partners, early sexual activity [10],
parity [11], long-term use of oral contraceptives [12–14],
smoking [15] and HIV/AIDS [16–18].
The link between cervical cancer and HPV infection
has been well established [16, 19–22]. From the more
than 100 types of HPV described, about 40 are known to
infect the genital tract and about 20 have been classified
as oncogenic to humans [23–25]. Persistent infection
with high-risk HPV has been considered as the neces-
sary condition for malignant transformation of the cer-
vical epithelium. In most studies, HPV16 and HPV18
are the predominant genotypes: they cause about 70 %
of precancerous lesions and cervical cancer [26]. In Sub-
Saharan Africa however, other oncogenic genotypes have
been reported [22, 27–32].
In most Sub-Saharan countries, data on the prevalence
and mortality of cervical cancer are either sparse or un-
available. Only 17 % of African countries have a national
programme and a specific budget for fighting cervical
cancer. And where such a cervical cancer programme
exists, the effective coverage may be low. In addition,
those women at the highest risk of developing cervical
cancer may have the most difficult access to care [33,
34]. The prevalence of precancerous and cancerous le-
sions has been studied in a small number of women in
the Democratic Republic of the Congo (DRC) [35–40].
Some of these reports include the prevalence of HPV
and/or cervical lesions in HIV-positive women [35, 40].
Because of the high burden of cervical cancer in Sub-
Saharan Africa, and presumably also in the DRC, the
primary objectives of this study were to: 1/ evaluate theprevalence of (pre)cancerous lesions, 2/ identify associ-
ated socio-demographic and behavioural factors and 3/
describe HPV types present among women in Kinshasa.
Results
Characteristics of study participants
The total number of participants was 1018. One hun-
dred thirty-one HIV-positive women were recruited at
HIV screening centres (group 1); 128 HIV-negative women
came from the same HIV screening centres (group 2); 539
women were recruited at large hospitals (group 3); and 220
were referred through small health centres (group 4). The
HIV status of the women in groups 3 and 4 was unknown.
Table 1 shows the age and age-related characteristics
of the participants. The mean age for all participants was
43.0 years (±12.8 standard deviation (SD)). The mean age
of menarche was 14.3 years (±1.9) and the age of the first
sexual intercourse was 18.5 years (±3.9). Table 2 summa-
rises the socio-demographical characteristics of the study
population. About half of the women were married, with
the highest percentage in group 3 (61.2 %) and the lowest
in group 2 (20.3 %). About one in six women was widowed
(18.0 %), and one in four was single. Concerning pregnan-
cies and parity, 44.0 % of the women reported six or more
pregnancies, 29.8 % responded to have six or more chil-
dren and 60.7 % reported to have had an abortion (not spe-
cified whether spontaneously or not).
Behaviour-related characteristics of the study popula-
tion are shown in Table 3. About half of the participants
reported to have had zero to two lifetime sexual partners.
In groups 1 and 2 (recruited at HIV screening centres),
more women reported to have had three or more sexual
partners (65.4 % and 61.2 % respectively). One out of five
women declared to have used hormonal contraceptives
(19.2 %); no information is available on the duration of its
use. One out of four women reported alcohol consump-
tion, including regular as well as irregular use. About the
same percentage (26.0 %) reported to use chemical prod-
ucts for vaginal care. The women in groups 3 and 4 were
also asked about the use of plants for vaginal care: 11.4 %
of the women confirmed the intravaginal application of
plants or vegetable products. Although the structured
interview did not include specific questions about the type
of plants that were used, some interviewers took note of
what some of the women reported. Terms that were
mentioned repeatedly in the local language Lingala in-
cluded: mbonzi-mbonzi (leaves of a tree), tangawisi (gin-
ger), tomate (tomato), lumba-lumba (medicinal leaves)
and ngai-ngai (sorrel).
Prevalence of low-grade squamous intraepithelial lesions
or worse (LSIL+)
In total, 76 of 1018 women were diagnosed with LSIL+
lesions (i.e. low- or high-grade squamous intraepithelial
Table 1 Age-related characteristics of the study population
Group 1 (n = 131) Group 2 (n = 128) Group 3 (n = 539) Group 4 (n = 220) Total
(n = 1018)HIV screening centres HIV screening centres Hospitals Health centres
HIV-positive women HIV-negative women HIV status unknown HIV status unknown
Age
Mean (years) ± SD 38.8 ± 9.1 29.4 ± 7.9 45.2 ± 11.0 48.0 ± 14.8 43.0 ± 12.8
Range (years) 20 – 59 17 - 51 20 – 76 20 – 82 17 - 82
n with available data 131 128 537 216 1012
Age of menarche
Mean (years) ± SD 15.0 ± 1.9 14.5 ± 1.5 14.2 ± 1.9 14.5 ± 2.0 14.3 ± 1.9
Range (years) 11 – 20 12- 17 10 – 21 10 - 20 10 - 21
n with available data 50 26 502 208 786
Age of first sexual intercourse
Mean (years) ± SD 17.2 ± 2.5 18.0 ± 3.2 18.8 ± 3.9 19.1 ± 4.5 18.5 ± 3.9
Range (years) 12 – 25 12 – 32 10 – 36 12 – 32 10 – 36
n with available data 127 125 523 207 982
n: number of participants with available data in each group; SD: standard deviation
Table 2 Socio-demographic characteristics of the study population
Group 1 (n = 131) Group 2 (n = 128) Group 3 (n = 539) Group 4 (n = 220) Total
(n = 1018)HIV screening centres HIV screening centres Hospitals Health centres
HIV-positive women HIV-negative women HIV status unknown HIV status unknown
n % n % n % n % n %
Marital status 130 128 533 217 1008
Married 43 (33.1) 26 (20.3) 326 (61.2) 120 (55.3) 515 (51.1)
Single 39 (30.0) 95 (74.2) 76 (14.3) 33 (15.2) 243 (24.1)
Widowed 34 (26.2) 4 (3.1) 92 (17.3) 51 (23.5) 181 (18.0)
Divorced 14 (10.8) 3 (2.3) 39 (7.3) 13 (6.0) 69 (6.9)
Formal employment 129 126 525 215 995
No 73 (56.6) 67 (53.2) 225 (42.9) 109 (50.7) 474 (47.6)
Yes 56 (43.4) 59 (46.8) 300 (51.7) 106 (49.3) 521 (52.4)
Number of pregnancies 128 126 517 219 990
0-2 29 (22.7) 87 (69.1) 131 (25.3) 53 (24.2) 300 (30.3)
3-5 42 (32.8) 28 (22.2) 124 (24.0) 60 (27.4) 254 (25.7)
6 or more 57 (44.5) 11 (8.7) 262 (50.7) 106 (48.4) 436 (44.0)
Number of childbirths 128 126 520 218 992
0-2 48 (37.5) 100 (79.4) 190 (36.5) 70 (32.1) 408 (41.1)
3-5 41 (32.0) 20 (15.9) 161 (31.0) 66 (30.3) 288 (29.0)
6 or more 39 (30.5) 6 (4.8) 169 (32.5) 82 (37.6) 296 (29.8)
Abortion 128 126 518 218 990
No 48 (37.5) 61 (48.4) 175 (33.8) 105 (48.2) 389 (39.3)
Yes 80 (62.5) 65 (51.6) 343 (66.2) 113 (51.8) 601 (60.7)
n: absolute number; %: percentage of participants in each study group and each category
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Table 3 Behaviour-related characteristics of the study population
Group 1 (n = 131) Group 2 (n = 128) Group 3 (n = 539) Group 4 (n = 220) Total
(n = 1018)HIV screening centres HIV screening centres Hospitals Health centres
HIV-positive women HIV-negative women HIV status unknown HIV status unknown
n % n % n % n % n %
Number of sexual partners 129 127 529 190 975
Zero to two 50 (38.8) 44 (34.7) 304 (57.5) 132 (69.5) 530 (54.4)
Three or more 79 (61.2) 83 (65.4) 225 (42.5) 58 (30.5) 445 (45.6)
Use of hormonal contraception 131 131 128 539 171 969 969
No 105 (80.2) 118 (92.2) 421 (78.1) 139 (81.3) 783 (80.8)
Yes 26 (19.8) 10 (7.8) 118 (21.9) 32 (18.7) 186 (19.2)
Alcohol consumption 131 127 529 138 925 925
No 123 (93.9) 99 (78.0) 378 (71.5) 87 (63.0) 687 (74.3)
Yes 8 (6.1) 28 (22.1) 151 (28.5) 51 (37.0) 238 (25.7)
Use of plants for vaginal care 539 212 751 751
No 513 (95.2) 153 (72.2) 666 (88.6)
Yes 26 (4.8) 59 (27.8) 85 (11.4)
Use of chemical products for
vaginal care
131 128 539 151 949
No 98 (74.8) 92 (71.9) 445 (82.6) 67 (44.4) 702 (74.0)
Yes 33 (25.2) 36 (28.1) 94 (17.4) 84 (55.6) 247 (26.0)
n: absolute number; %: percentage of participants in each study group and each category
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the HIV-positive women of group 1, the prevalence of
LSIL+ was 31.3 % (95 % confidence interval (CI): 24.0 % –
39.7 %). Among the HIV-negative women recruited in the
same clinics (group 2), the LSIL+ prevalence was 3.9 %
(95 % CI: 1.7 % – 8.8 %). Among the participants coming
from the large hospitals (group 3), the prevalence wasTable 4 Numbers and proportions of different lesions according to
Group 1 (n = 131) Group 2 (n = 128)
HIV screening centres HIV screening centres
HIV-positive women HIV-negative women
n (%) n (%)
NILM 80 (61.1) 117 (91.4)
ASCUS 9 (6.9) 5 (3.9)
ASC-H 1 (0.8) 1 (0.8)
LSIL 2 (1.5) 0 (0.0)
HSIL 30 (22.9) 5 (3.9)
Ca 9 (6.9) 0 (0.0)
Subtotal: LSIL+ 41 (31.3) 5 (3.9)
NILM negative for intraepithelial lesion and malignancy
ASCUS atypical squamous cells of undetermined significance
ASC-H atypical squamous cells, cannot rule out high-grade lesion
LSIL low-grade squamous intraepithelial lesion
HSIL high-grade squamous intraepithelial lesion
Ca Carcinoma
LSIL+ cytology findings compatible with (pre)cancerous lesions (includes low- and h3.9 % (95 % CI: 2.6 % – 5.9 %) and among the women
coming via smaller health centres (group 4), 4.1 % (95 %
CI: 2.2 % – 7.6 %). Among the women with unknown or
negative HIV status, lesions classified as ASCUS (atypical
squamous cells of undetermined significance) or ASC-H
(atypical squamous cells, cannot rule out high-grade le-
sion) were more frequent than LSIL+ lesions (Table 4).the Bethesda 2001 classification, per study group
Group 3 (n = 539) Group 4 (n = 220) Total
(n = 1018)Hospitals Health centres
HIV status unknown HIV status unknown
n (%) n (%) 1018 (%)
449 (83.3) 188 (85.5) 834 (81.9)
46 (8.5) 19 (8.6) 79 (7.8)
23 (4.3) 4 (1.8) 29 (2.9)
0 (0.0) 0 (0.0) 2 (0.2)
17 (3.2) 5 (2.3) 57 (5.6)
4 (0.7) 4 (1.8) 17 (1.7)
21 (3.9) 9 (4.1) 76 (7.5)
igh-grade squamous intraepithelial lesions and carcinoma)
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associated with LSIL+ lesions
In each of the four groups, bivariate associations were
assessed between all explanatory factors (age, socio-
demographic and behaviour-related characteristics) and
the presence of LSIL+ lesions. Crude odds ratios (ORs)
are given in Table 5. Explanatory factors with a P-value
of <0.2 were included in a model of multiple logistic re-
gression (one model per study group). The adjusted ORs
are given in Table 6. None of these associations reached
statistical significance on multiple logistic regression.
All participants were then analysed together using
generalised estimating equations (GEE) to account for
clustering within the study groups. Also in the GEE ana-
lysis, all factors with a P-value <0.2 on bivariate evalu-
ation were included in a multivariable model. The final
GEE model (one model for all the study groups) in-
cluded history of abortion (adjusted OR 1.60; 95 % CITable 5 Bivariate associations between socio-demographic and beh
study group
Group 1 (n = 131) G
HIV screening centres H
HIV-positive women H
Crude OR 95 % CI C
Age (in years)a 0.99 0.95 - 1.03 1
Age of menarche (in years)a 0.94 0.67 - 1.30 2
Age of first sexual intercourse 0.89* 0.76 - 1.05 1
Marital status married 1.00 1
single 0.56 0.21 - 1.48 0
widowed 1.16 0.45 - 2.94 8
divorced 0.75 0.20 - 2.79 §
Formal employment 0.75 0.35 - 1.61 1
Number of pregnancies 0 - 2 1.00 1
3 - 5 1.31 0.47 - 3.70 1
6 or more 1.31 0.49 - 3.51 1
Number of childbirths 0 - 2 1.00* 1
3 - 5 1.08 0.96 - 5.77 8
6 or more 1.18 0.45 - 3.06 §
Abortion 1.70* 0.77 - 3.78 1
Three or more lifetime sexual partners 1.26 0.58 - 2.74 2
Hormonal contraception 1.21 0.49 - 3.00 3
Alcohol consumption 0.30 0.04 - 2.49 2
Plants for vaginal care † †
Chemicals for vaginal care 0.63 0.26 - 1.55 §
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and
OR odds ratio; 95 % CI 95 % confidence interval of the odds ratio
aAge was treated as a continuous variable. Interpretation, e.g. in group 2: the odds
**P-value of Wald, chi-squared or Fisher exact test < 0.05
*P-value of Wald, chi-squared or Fisher exact test is not significant but is less than 0
§Odds ratio could not be calculated because there were cells without observations
†Data about use of plants for vaginal care were not available in groups 1 and 20.97 – 2.63), more than three sexual partners (adjusted
OR 1.29; 95 % CI 0.83 – 1.99) and use of chemical prod-
ucts for vaginal care (adjusted OR 0.65; 95 % CI 0.37 –
1.14). Adding age to the model did not substantially
change the ORs. None of the associations in this model
reached statistical significance (Table 6).
The use of plants for vaginal care could only be evalu-
ated in groups 3 and 4 because this information was not
available for the women in the other groups. In a multiple
logistic regression model including the use of plants, alco-
hol consumption and having had three or more sexual
partners, the adjusted OR for the association between the
use of plants for vaginal care and the presence of LSIL+
lesions was 2.70 (95 % CI 1.04 – 7.01; Table 6).
Determination of HPV DNA and HPV typing
The following cytology results were classified as ASCUS+
and the corresponding samples were submitted for HPVavioural characteristics and presence of LSIL+ lesions, per
roup 2 (n = 128) Group 3 (n = 539) Group 4 (n = 220)
IV screening centres Hospitals Health centres
IV-negative women HIV status unknown HIV status unknown
rude OR 95 % CI Crude OR 95 % CI Crude OR 95 % CI
.11** 1.00 - 1.24 1.02 0.98 - 1.07 1.02 0.97 - 1.06
.87 0.36 - 23.07 1.03 0.82 - 1.30 0.80 0.55 - 1.15
.09 0.86 - 1.38 1.01 0.90 - 1.13 0.84* 0.68 - 1.06
.00* 1.00 1.00
.82 0.08 - 8.18 2.23 0.74 - 6.71 1.23 0.24 - 6.38
.33 0.41 - 170.67 1.44 0.44 - 4.69 §
1.71 0.36 - 8.10 1.58 0.18 - 14.28
.74 0.28 - 10.79 1.92* 0.73 - 5.03 0.28* 0.06 - 1.38
.00** 1.00 1.00
.96 0.14 - 18.04 1.06 0.33 - 3.38 0.28 0.03 - 2.80
0.01 1.18 - 75.36 0.66 0.22 - 1.93 0.83 0.19 - 3.59
.00** 1.00 1.00
.65 1.34 - 55.65 0.31 0.15 - 1.70 0.70 0.11 - 4.31
1.00 0.38 - 2.65 1.15 0.25 - 5.30
.43 0.23 - 8.85 2.09* 0.69 - 6.35 1.17 0.31 - 4.48
.18 0.24 - 20.10 2.27* 0.92 - 5.57 0.91 0.17 - 4.82
.17 0.32 - 31.40 1.12 0.40 - 3.12 §
.46 0.39 - 15.51 1.57 0.64 - 3.87 4.62* 0.86 - 24.75
3.59* 0.99 – 13.05 2.15 0.56 – 8.31
* 0.49 0.11 - 2.13 2.06 0.39 - 10.95
high-grade squamous intraepithelial lesions and carcinoma)
of LSIL+ lesions increased with a factor 1.11 for each one-year increase in age
.2
Table 6 Multivariable evaluations of the association between explanatory variables and the presence of LSIL+ lesions
Type of analysis Study groups included Number of
observations*
Explanatory variables included in
the model
Adjusted OR 95 % CI
Logistic regression 1 (HIV screening centres
HIV-positive women)
124 Age of first sexual intercoursea 0.86 0.72 – 1.02
Number of pregnancies
0 – 2 1
3 – 5 0.95 0.31 – 2.86
6 or more 0.83 0.28 – 2.44
Abortion 1.98 0.83 – 4.75
Logistic regression 2 (HIV screening centres
HIV-negative women)
123 Agea 1.11 0.95 – 1.31
Marital status
married 1
single 5.26 0.27 – 102.32
widowed 4.34 0.18 – 105.99
divorced §
Number of pregnancies
0 – 2 1
3 – 5 1.15 0.07 – 18.34
6 or more 4.27 0.22 – 81.82
Logistic regression 3 (Hospitals HIV status
unknown)
502 Formal employment 2.08 0.74 – 5.88
Abortion 1.65 0.53 – 5.14
≥3 lifetime sexual partners 1.75 0.69 – 4.46
Plants for vaginal care 2.85 0.75 – 10.82
Logistic regression 4 (Health centres HIV
status unknown)
203 Age of first sexual intercoursea 0.86 0.68 – 1.07
Formal employment 0.30 0.06 – 1.50
GEE 1, 2 3 and 4 886 Abortion 1.60 0.97 – 2.63
≥3 lifetime sexual partners 1.29 0.83 – 1.99
Chemicals for vaginal care 0.65 0.37 – 1.14
Logistic regression 3 and 4 643 Alcohol consumption 1.76 0.80 – 3.86
≥3 lifetime sexual partners 1.58 0.72 – 3.46
Plants for vaginal care 2.70 1.04 – 7.01**
LSIL+: cytology findings compatible with (pre)cancerous lesions (includes low- and high-grade squamous intraepithelial lesions and carcinoma)
OR odds ratio; 95 % CI 95 % confidence interval of the odds ratio
GEE: generalized estimating equations (population-averaged model; group variable: study group)
aAge was treated as a continuous variable
§ Odds ratio could not be calculated because there were cells without observations
**P-value of Wald test < 0.05
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HIV-positive group, 50 out of the 52 ASCUS+ samples
contained HPV DNA. HPV16 was found in 10 out of 50
samples, and HPV18 in 5 (Table 7). Other genotypes that
were frequently detected were HPV35 (n = 12), HPV52
(n = 12), HPV68 (n = 12), HPV51 (n = 10), and HPV31
(n = 9). In the groups of women with negative or unknown
HIV status, 50 samples were tested with INNO-LiPA of
which 40 contained detectable HPV DNA (Table 7). Here,
the most frequently detected genotypes were HPV52 (n =
10), HPV35 (n = 6), HPV16 (n = 3), HPV18 (n = 5),HPV51 (n = 5), and HPV54 (n = 5). In addition to the
three samples in which HPV16 was detected through the
INNO-LiPA test, there were three samples in which both
the Abbot Real Time and the GenoID test indicated the
presence of HPV16.
In groups 2, 3 and 4, 55 % of samples which tested
positive for HPV DNA contained one single HPV type.
Two genotypes were found in 23 % of the samples, three
genotypes in 9 %, four in 7 % and more than four in 7 %
of HPV-DNA positive samples. In the HIV-positive
group (group 1), a single HPV infection occurred only in
Table 7 HPV genotyping results for women with ASCUS+
cytology
HPV genotype Group 1 (HIV-positive
women)
Groups 2, 3 and 4 (women
with unknown or negative
HIV status)
Number of women
with ASCUS + = 52
Number of women with
ASCUS + = 133
Number of samples in
which HPV typing results
were available = 50
Number of samples in
which HPV typing results
were available = 40
6 3 (6 %) 0 (0 %)
11 2 (4 %) 1 (3 %)
16 10 (20 %) 3 (8 %)a
18 5 (10 %) 5 (13 %)
31 9 (18 %) 2 (5 %)
33 6 (12 %) 4 (10 %)
35 12 (24 %) 6 (15 %)
39 6 (12 %) 4 (10 %)
40 1 (2 %) 1 (3 %)
43 2 (4 %) 0 (0 %)
44 5 (10 %) 0 (0 %)
45 7 (14 %) 2 (5 %)
51 10 (20 %) 5 (13 %)
52 12 (24 %) 10 (25 %)
53 5 (10 %) 1 (3 %)
54 3 (6 %) 5 (13 %)
56 6 (12 %) 3 (8 %)
58 7 (14 %) 0 (0 %)
59 2 (4 %) 1 (3 %)
66 7 (14 %) 4 (10 %)
68 12 (24 %) 3 (8 %)
69 1 (2 %) 1 (3 %)
70 5 (10 %) 1 (3 %)
74 4 (8 %) 4 (10 %)
82 0 (0 %) 1 (3 %)
HPV human papillomavirus
ASCUS+ includes: atypical squamous cells of undetermined significance
(ASCUS); atypical squamous cells; cannot rule out high-grade lesion (ASC-H);
low- grade squamous intraepithelial lesions (LSIL), high-grade squamous
intraepithelial lesions (HSIL) and carcinoma
aIn addition to the three samples in which HPV16 was detected through the
INNO-LiPA test, there were three samples in which both the Abbot Real Time
and the GenoID test indicated the presence of HPV16
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38 %, three in 9 %, four in 16 % and more than four in
18 % of the samples.
Discussion
The present study was performed to assess the preva-
lence of LSIL+ lesions and to identify associated factorsin different groups of women in Kinshasa. The preva-
lence of LSIL+ lesions ranged from approximately 4 % in
women with unknown or negative HIV status to 31 % in
HIV-positive women. We found an association between
the practice of intravaginal insertion of plants and the
presence of LSIL+. HPV types 16 and 18 which are known
to cause cervical cancer in many countries worldwide ap-
pear to be less predominant in women in Kinshasa.
The prevalence of LSIL+ lesions that we found in the
current study in women with unknown or seronegative
HIV status (4 %) is consistent with the few studies previ-
ously performed in Kinshasa (3 % and 5 %) [35, 36] and
in Bukavu in the eastern part of the country (7 %) [37].
Numbers of the same order of magnitude have been pub-
lished in other Sub-Saharan countries. A prevalence be-
tween 4 and 10 % was found in studies in Burkina-Faso,
Nigeria, Tanzania, South Africa, Malawi and Kenya [29,
41–49]. Higher prevalences (16 %) were reported in stud-
ies in the Central African Republic and Uganda [50, 51].
These reports and our findings highlight the high and
heterogeneous frequency of (pre) cancerous lesions in
different countries of Sub-Saharan Africa. Furthermore, in
our study, lesions classified as ASCUS and ASC-H were
also frequent (more frequent than LSIL+) among women
with negative or unknown HIV status.
Cervical cancer is known to be more frequent among
HIV-positive women. In the DRC, it is estimated that
1.9 % of the adult women are HIV infected, with differ-
ences between women living in urban areas (2.4 %) and
rural areas (1.0 %) [52]. We found a prevalence of LSIL+
lesions of 31 % in HIV-seropositive women. This finding
is consistent with an earlier result (27 %) described in a
small group of seropositive women in Kinshasa [35]. Also
in other Sub-Saharan countries (pre)cancerous lesions
were about five times more frequent in HIV-positive than
in HIV-negative women [41, 42, 45, 48–51, 53].
Several demographic, economical and behavioural risk
factors have been studied in relation to cervical cancer.
Most of them may influence the risk of cancer through
their effects on the risk of HIV and HPV infection. In
the current study, we found a significant association be-
tween the intravaginal application of plant products and
the presence of LSIL+ lesions. It is a frequent practice in
Sub-Saharan Africa to use herbs, leaves and bark of trees
to reduce vaginal lubrication and increase friction during
sexual intercourse (dry sex) [54–59]. The perception is
that dry sex increases sexual enjoyment. A study in the
DRC revealed that one third of the women had used
intra-vaginal substances at some time [55]. Another Con-
golese study looked into how specific plants are used and
what the chemical and microbiological consequence of
this traditional practice could be [60].
Most of the studies about the vaginal use of plants
have been done in relation to the risk of HIV infection.
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environment may partially explain the different HIV
transmission probabilities that are observed across popu-
lations [61]. Similar mechanisms may play a role in
transmission and clearance of HPV [62–64]. The inser-
tion of plant products and the increased friction during
dry sex may alter the vaginal microbiota and cause trau-
matic microlesions in the vaginal wall facilitating the
entry of HPV [62–64].
The association between HPV infection and cervical
cancer is well established, but the specific HPV geno-
types that are involved in neoplasia differ across popula-
tions. The HPV types that have been most frequently
linked to cervical cancer are: 16, 18, 31, 33, 45, 52 and
58 [53, 65]. HPV16 and 18 are responsible for 70 % of
precancerous lesions and cervical cancer worldwide and
consequently, these are the HPV types which the vaccine
development has focused on. Nevertheless, our study
suggests that HPV16 and 18 are less frequent (maximally
30 % of women with ASCUS+) and that HPV types 35, 52
and 68 are more predominant than in other regions.
Other studies in the DRC have also described specific pat-
terns of HPV types [38, 40].
In other Sub-Saharan countries, the frequency of
HPV16 and 18 varies. Some countries have reported pat-
terns that resemble the situation in Europe and the
United States [22, 48, 66, 67], whereas in other coun-
tries, HPV types other than 16 and 18 appear to be more
prominent [29, 47, 68, 69].
The DRC is a large country that is facing many com-
plex problems at the same time. As a consequence,
cervical cancer is not getting the attention that would be
required for adequate disease control. Yet, the burden
caused by cervical cancer in the DRC would justify a
coordinated control strategy. This study together with a
previous report illustrates that women in Kinshasa are
willing to participate in prevention and control activities
[70]. Interventions that could help to reduce the morbid-
ity and mortality of cervical cancer include vaccination
for HPV, systematic screening and early treatment. The ef-
fectiveness of such interventions may benefit from further
research into the epidemiology of oncogenic HPV types
and modifiable risk factors such as the use of plants for
intimate care.
Conclusion
Our work illustrates that the prevalence of (pre)cancer-
ous lesions in women from different districts in Kinshasa
is approximately 4 %. In HIV-positive women, the preva-
lence is about eight times higher. Traditional practices
concerning vaginal hygiene may increase the risk of malig-
nant transformation. More extensive studies, including
rural areas, are needed to unravel the contribution of dif-
ferent HPV types in the development of cervical cancer.Methods
Study design, setting and participants
We performed a cross-sectional study on the prevalence
of precancerous and cancerous lesions of the uterine
cervix in four groups of women in Kinshasa. The first
two groups consisted of women who participated in a
voluntary screening programme for HIV in the ACS/
AMO-CONGO centre (Action Communautaire contre
le Sida/Avenir Meilleur pour les Orphelins du Sida au
Congo) and in the Centre Hospitalier Monkole 3. Women
who visited these centres for HIV screening and care be-
tween September 2006 and January 2007 were invited to
participate in free cervical cancer screening. The first
group (n = 131) consisted of women who were found to
be seropositive for HIV; the second group (n = 128) con-
sisted of HIV-seronegative women. The diagnosis of HIV
was based on two rapid tests (Determine®HIV-1/2 (Ab-
bott) and OraQuick®HIV-1/2 (OraSure Technologies))
combined with one of the following serological tests: Viro-
nostika® Uni-Form II Plus O (BioMérieux), Enzygnost®
Anti-HIV ½ Plus (Siemens), or Inno-Lia HIVI/II Score
(Inno-LIA®, Innogenetics). The third group (n = 539) con-
sisted of women who consulted the gynaecology depart-
ment of the Provincial Reference Hospital of Kinshasa
(Hôpital Provincial Général de Référence de Kinshasa,
HPGRK) and the Ngaliema hospital. Both hospitals are
large state hospitals in the centre of the city. Data were
collected from July to August 2009. At that time, a sensi-
tisation campaign for free cervical screening was broad-
cast on television, posters advertising cervical cancer
screening were shown at the hospitals, and a symposium
on cervical cancer took place at the HPGRK. The partici-
pants of the fourth group (n = 220) were recruited via
primary health care centres in the communities of
Kimbanseke, Kisenso, Ndjili and Lemba, located in the
poorer suburbs of the city. Data were collected from
September 2012 to January 2013 after a campaign in local
churches for free cervical cancer screening.
All women older than 17 who were willing to partici-
pate in the study and for whom a liquid-based cytology
(LBC) result was available were included in the analysis.
Variables, data sources and measurement
Cytology
Cytology was the main outcome variable. Cervical smears
were collected with Cervex Brush and conserved in Thin-
Prep solution for LBC and HPV typing. Samples were kept
at 4 °C. ThinPrep vials were transferred to the Pathology
Laboratory of the University Hospital of Ghent, Belgium,
for further analysis. The collected smears were independ-
ently read and interpreted by two pathologists. The pa-
thologists were not aware of the HIV and HPV status at
the time of reading the microscopy slides. In case of
discrepancy, the slides were reread by both pathologists
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ported according to the Bethesda Classification 2001 of
cervical pathology. Women with cytology results indicat-
ing LSIL (low-grade squamous intraepithelial lesion),
HSIL (high-grade squamous intraepithelial lesion) and in-
vasive carcinoma were considered to have precancerous
or cancerous lesions and classified as LSIL+ (according to
[71]). Women with ASCUS (atypical squamous of un-
determined significance), ASC-H (atypical squamous, can-
not rule out high-grade lesion) results or worse (ASCUS+)
underwent HPV-DNA determination. Women with NILM
(negative for intraepithelial lesion and malignancy) or in-
flammation were considered to be free of cancer.
Determination of HPV DNA and HPV typing
HPV typing was done in participants with ASCUS+
cytology results. Samples from women with ASCUS and
ASC-H were included in the HPV evaluation as the
European guidelines recommend to determine HPV DNA
in these groups. INNO-LiPA HPV Genotyping Extra
(Innogenetics, Zwijnaarde, Belgium) was used for HPV
typing. It is molecular technique based on the principle of
reverse hybridisation designed to recognize fifteen high-
risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68, 73 and 82), three probable high-risk HPV types
(26, 53 and 66), seven low-risk HPV types (6, 11, 40, 43,
44, 54 and 70) and three non-classified HPV types (69, 71
and 74).) The testing strategies varied across the study
groups. In groups 1 and 2, INNO-LiPA Genotyping was
done for all ASCUS+ cases. In groups 3 and 4, the INNO-
LiPA test, due to its high cost, was only done if two other
tests gave discordant results (Abbott Real Time High Risk
HPV test (Abbott, Madison, USA) and Full Spectrum
PCR HPV Amplification and Detection/Genotyping
System (GenoID Molecular Diagnostics Laboratory,
Budapest, Hungary)). We present all available INNO-
LiPA results because this test detects many different
HPV types [72]. Concordant Abbott and GenoID results
for HPV16 and HPV18 are also reported.
Socio-economic, gynaecological/medical and behaviour
variables
Socio-economic and behaviour characteristics that were
studied in association with the presence or absence of
LSIL+ were: age, age of menarche, age of first sexual
contact, marital status, formal employment, life-time
number of sexual partners, use of products for vaginal
care (chemicals and products from plants), alcohol con-
sumption (no alcohol versus any consumption), number
of pregnancies, number of childbirths, and history of
abortion (without discrimination between spontaneous
or provoked). Concerning the practice of intravaginal
application of plants, information was only available for
groups 3 and 4.The variables “age”, “age of menarche” and “age of first
sexual contact” follow a relatively normal distribution
and are presented and analysed as continuous variables.
The variables “number of sexual partners”, “number of
pregnancies” and “number of deliveries” follow a clearly
abnormal distribution and are presented and analysed as
categorical variables.
Information about the socio-economic situation and
behaviour characteristics was obtained through a struc-
tured interview by medical doctors. Interviewers followed
a training session before the start of the study.
Statistical analysis
The prevalence of LSIL+ lesions with 95 % confidence
intervals (95 % CI, Wilson score method without continu-
ity correction) is reported for each of the four groups.
Next, we used bivariate and multiple logistic regression to
assess the association between socio-demographic and
behaviour variables and the presence of LSIL+ lesions
within each of the four groups. Finally, we analysed all
participants together using generalized estimating equa-
tions (GEE) to account for clustering within the groups.
The results of all logistic regression and GEE analyses are
reported as odds ratios (OR) with 95 % confidence inter-
vals (95 % CI). Data was missing for some participants in
some of the explanatory variables; for each of the analyses,
the number of included participants is given. We used
Stata/IC 10.1 for data analysis.
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